blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

Latvia joins the Federated Register
Click here for more information on the Federated Register.

2025-04-16

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3484853

EP3484853 - METHOD FOR PRODUCING A POLYMORPHIC FORM OF 3-[5-AMINO-4-(3-CYANOBENZOYL)-PYRAZOL-1-YL]-N-CYCLOPROPYL-4-METHYLBENZAMIDE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.02.2022
Database last updated on 05.05.2025
FormerThe patent has been granted
Status updated on  19.03.2021
FormerGrant of patent is intended
Status updated on  18.11.2020
FormerExamination is in progress
Status updated on  03.04.2020
FormerRequest for examination was made
Status updated on  19.04.2019
FormerThe international publication has been made
Status updated on  20.01.2018
Formerunknown
Status updated on  01.08.2017
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024  [2024/42]
Applicant(s)For all designated states
Mereo BioPharma 1 Limited
1 Cavendish Place
London, Greater London W1G 0QF / GB
[2019/21]
Inventor(s)01 / SULEIMAN, Osama
Johnson Matthey Plc.
Fine Chemicals Division (Pharmorphix)
250 Cambridge Science Park
Milton Road
Cambridge Cambridgeshire CB4 0WE / GB
02 / PEREZ, Lucia Romero
Johnson Matthey Plc.
Johnson Matthey Chemical Product
Orchard Road
Royston Hertfordshire SG8 5HE / GB
03 / HARLACHER, Cornelius Stephan
Zihlackerstrasse 60
4153 Reinach / CH
04 / JONES, Stewart
Mereo Biopharma Group plc
4th Floor
1 Cavendish Place
London Greater London W1G 0QF / GB
 [2019/21]
Representative(s)Gill Jennings & Every LLP
The Broadgate Tower
20 Primrose Street
London EC2A 2ES / GB
[2019/21]
Application number, filing date17742277.113.07.2017
[2019/21]
WO2017GB52055
Priority number, dateGB2016001223814.07.2016         Original published format: GB 201612238
[2019/21]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018011578
Date:18.01.2018
Language:EN
[2018/03]
Type: A1 Application with search report 
No.:EP3484853
Date:22.05.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 18.01.2018 takes the place of the publication of the European patent application.
[2019/21]
Type: B1 Patent specification 
No.:EP3484853
Date:21.04.2021
Language:EN
[2021/16]
Type: B9 Corrected patent specification 
No.:EP3484853
Date:28.07.2021
[2021/30]
Search report(s)International search report - published on:EP18.01.2018
ClassificationIPC:C07D231/38, A61K31/415, A61P29/00
[2019/21]
CPC:
C07D231/38 (EP,IL,KR,RU,US); A61K31/415 (EP,IL,KR,RU); A61P25/00 (EP,KR);
A61P29/00 (EP); C07B2200/13 (IL,KR,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/21]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:VERFAHREN ZUR HERSTELLUNG EINER POLYMORPHEN FORM VON 3-[5-AMINO-4-(3-CYANOBENZOYL)-PYRAZOL-1-YL]-N-CYCLOPROPYL-4-METHYLBENZAMID[2019/21]
English:METHOD FOR PRODUCING A POLYMORPHIC FORM OF 3-[5-AMINO-4-(3-CYANOBENZOYL)-PYRAZOL-1-YL]-N-CYCLOPROPYL-4-METHYLBENZAMIDE[2019/21]
French:PROCÉDÉ DE PRODUCTION D'UNE FORME POLYMORPHE DE 3- [5-AMINO-4-(3-CYANOBENZOYL)-PYRAZOL-1-YL]-N-CYCLOPROPYL-4-MÉTHYLBENZAMIDE[2019/21]
Entry into regional phase12.02.2019National basic fee paid 
12.02.2019Designation fee(s) paid 
12.02.2019Examination fee paid 
Examination procedure12.02.2019Examination requested  [2019/21]
12.02.2019Date on which the examining division has become responsible
31.07.2019Amendment by applicant (claims and/or description)
07.04.2020Despatch of a communication from the examining division (Time limit: M04)
24.07.2020Reply to a communication from the examining division
17.08.2020Despatch of a communication from the examining division (Time limit: M04)
08.09.2020Reply to a communication from the examining division
19.11.2020Communication of intention to grant the patent
10.03.2021Fee for grant paid
10.03.2021Fee for publishing/printing paid
10.03.2021Receipt of the translation of the claim(s)
Opposition(s)24.01.2022No opposition filed within time limit [2022/13]
Fees paidRenewal fee
15.07.2019Renewal fee patent year 03
14.07.2020Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL21.04.2021
CY21.04.2021
EE21.04.2021
HR21.04.2021
LT21.04.2021
LV21.04.2021
MK21.04.2021
MT21.04.2021
RS21.04.2021
SI21.04.2021
SK21.04.2021
SM21.04.2021
BG21.07.2021
IS21.08.2021
[2024/42]
Former [2024/22]AL21.04.2021
CY21.04.2021
EE21.04.2021
HR21.04.2021
LT21.04.2021
LV21.04.2021
MK21.04.2021
RS21.04.2021
SI21.04.2021
SK21.04.2021
SM21.04.2021
BG21.07.2021
IS21.08.2021
Former [2023/30]AL21.04.2021
CY21.04.2021
EE21.04.2021
HR21.04.2021
LT21.04.2021
LV21.04.2021
RS21.04.2021
SI21.04.2021
SK21.04.2021
SM21.04.2021
BG21.07.2021
IS21.08.2021
Former [2022/29]AL21.04.2021
EE21.04.2021
HR21.04.2021
LT21.04.2021
LV21.04.2021
RS21.04.2021
SI21.04.2021
SK21.04.2021
SM21.04.2021
BG21.07.2021
IS21.08.2021
Former [2022/26]AL21.04.2021
EE21.04.2021
HR21.04.2021
LT21.04.2021
LV21.04.2021
RS21.04.2021
SK21.04.2021
SM21.04.2021
BG21.07.2021
IS21.08.2021
Former [2022/23]EE21.04.2021
HR21.04.2021
LT21.04.2021
LV21.04.2021
RS21.04.2021
SK21.04.2021
SM21.04.2021
BG21.07.2021
IS21.08.2021
Former [2022/10]EE21.04.2021
HR21.04.2021
LT21.04.2021
LV21.04.2021
RS21.04.2021
SK21.04.2021
SM21.04.2021
BG21.07.2021
IS22.12.2021
Former [2022/07]HR21.04.2021
LT21.04.2021
LV21.04.2021
RS21.04.2021
SM21.04.2021
BG21.07.2021
IS21.08.2021
Former [2021/51]HR21.04.2021
LT21.04.2021
LV21.04.2021
RS21.04.2021
BG21.07.2021
IS21.08.2021
Former [2021/49]HR21.04.2021
LT21.04.2021
LV21.04.2021
BG21.07.2021
Former [2021/47]LT21.04.2021
BG21.07.2021
Former [2021/46]LT21.04.2021
Cited inInternational search[Y]WO2005009973  (TRIAD THERAPEUCTICS INC [US], et al);
by applicantWO2005009973
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.